Metraipolis › archive › dc_bbe4aa468d75

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor… — Europe PMC PMID:41858341

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41858341
DOI
10.3389/fonc.2026.1748566
License (as archived)
solo-consultazione
Archived
2026-10-07T22:04:14.721Z
SHA-256 of the archived text
351c5b7711ff59f75ba97ae707726636e43ca3a754865271c7b5df600186d7e5
Stable URL of this page
https://metraipolis.com/documento/dc_bbe4aa468d75

How to cite

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor… — Europe PMC PMID:41858341 — Europe PMC (en), https://europepmc.org/article/MED/41858341 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bbe4aa468d75 (Metraipolis archive dc_bbe4aa468d75, sha256 351c5b7711ff59f75ba97ae707726636e43ca3a754865271c7b5df600186d7e5)
BibTeX
@misc{dcbbe4aa468d75,
  title = {Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor… — Europe PMC PMID:41858341},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41858341},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bbe4aa468d75; sha256 351c5b7711ff59f75ba97ae707726636e43ca3a754865271c7b5df600186d7e5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41858341. Agents can read the archived copy with the MCP tool read_document.